Genfit shares fall 3% and drop back below their 20-day moving average, down 6% over one week
The Lille-based biotech specialising in liver and metabolic diseases is retreating at midday, in a very poorly oriented Paris session. The move comes after a month of strong recovery, while third-quarter publications remain recent.
A pullback that brings the stock back below its 20-day moving average after a month of rebound
The price of Genfit loses 3.23% to €10.20 in intraday trading. The stock ranks near the bottom of the SBF 120, which itself falls 1.31%, and holds a position that does not warrant any superlative.
Despite this decline, the gain remains 22.74% over one month, but the stock gives up 5.9% over the week. It thus falls back below its 20-day moving average (€10.69, a gap of 4.58%) while remaining above its 50-day moving average (€9.99). This configuration reflects a loss of momentum in the rebound started at the end of October, which the previous recovery session had not fully confirmed.
Ipsen's Iqirvo royalties support the case, financing extends beyond 2028
When publishing its third-quarter information on 5 November 2026, Genfit reported that royalties on Iqirvo sales had risen 188% over nine months, to €36.3 million, while total revenue declined to €36.4 million from €39.2 million a year earlier. This publication specified that these revenues allow the financing of activities beyond the end of 2028.
Among the risks cited is the dependence on Ipsen, which accounts for nearly all of the royalties. The company also mentions the launch of phase 2 trials in ACLF and cholangiocarcinoma, with results expected in 2027. In terms of price levels, the support at €7.83 and the resistance at €11.46 frame the current share price.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorPharmacie et biotechnologies›Biotechnologies
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 36,4 millions d'euros
Quarterly revenue: 36,4 millions d'euros
Revenue growth: -7,1 %
Guidance from the release
« conforte GENFIT dans son anticipation de la réception possible d'un nouveau paiement d'étape commercial » ; « permettent un financement des activités au-delà de fin 2028 »
Risks mentioned
Dépendance envers Ipsen pour la majorité des revenus (redevances sur ventes d'Iqirvo), qui représente 99,7% des revenus de redevances
Paiements d'étape commerciaux futurs soumis à conditions réglementaires et commerciales incertaines
Besoin de financement au-delà de 2028 dépendant de la croissance des ventes d'élafibranor et de l'adoption commerciale des technologies NIS™
Opportunities identified
Croissance des ventes d'Iqirvo auprès d'Ipsen (188% YoY sur redevances) avec pic de ventes révisé à 1 milliard d'euros
Medicare a approuvé le remboursement du test NASHnext® en août 2026, ouvrant un marché potentiel estimé à plus de 1,5 milliard de dollars à horizon 2033
Lancement de trois essais cliniques de Phase 2 (ACLF, CCA) avec résultats attendus en 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.